Nifecard HL tablets 30mg, No. 30
Expiration Date: 11/2025
Russian Pharmacy name:
Нифекард ХЛ таблетки 30мг, №30
arterial hypertension;
IHD: stable exertional angina, vasospastic angina (Prinzmetal's angina).
Inside, without chewing, do not crush or divide. The dosage regimen is set individually.
The dose of the drug NifecardЃHL - 1 tab. (30 or 60 mg) once a day. The selection of the dose begins at 30 mg / day, the correction is carried out at intervals of 7-14 days.
The maximum daily dose is 90 mg.
| Controlled-release film-coated tablets | 1 tab. |
| active substance: | |
| nifedipine | 30 mg |
| 60 mg | |
| excipients: povidone - 75/100 mg; sodium lauryl sulfate - 2.4 / 4.8 mg; hypromellose - 185.8 mg (tablets 30 mg); hypromellose-2906 - 203.84 mg and hypromellose-2208 - 123.36 mg (60 mg tablets); LudipressЃ (lactose monohydrate - 93%, povidone - 3.5%, crospovidone - 3.5%) - 70/50 mg; magnesium hydrosilicate (talc) - 6 mg; magnesium stearate - 0.8 / 2 mg | |
| shell: hypromellose phthalate (hydroxypropyl methylcellulose phthalate) - 18.2 / 40 mg; triethyl citrate - 1.8 / 4 mg; hypromellose-2910 (hydroxypropyl methylcellulose - 3 / 4.5 mg; hyprolose (hydroxypropyl cellulose) - 3 / 4.5 mg; macrogol (polyethylene glycol) - 1 / 1.5 mg; magnesium hydrosilicate (talc) - 0.5 / 0.75 mg; titanium dioxide - 1.93 / 2.9 mg; iron dye yellow oxide - 0.57 / 0.85 mg |
in a blister 10 pcs.; in a pack of cardboard 2 or 3 blisters.
hypersensitivity to nifedipine or drug components and other 1,4-dihydropyridine derivatives;
severe arterial hypotension (SBP below 90 mm Hg);
severe stenosis of the aortic valve;
chronic heart failure in the stage of decompensation, cardiogenic shock (risk of developing myocardial infarction), acute period of myocardial infarction (during the first 4 weeks);
I trimester of pregnancy, lactation period.
With caution: severe stenosis of the aortic orifice or mitral valve, hypertrophic obstructive cardiomyopathy, severe tachycardia, sick sinus syndrome, malignant arterial hypertension, myocardial infarction with left ventricular failure, unstable angina pectoris, concomitant administration of beta-adrenergic blocking agents, or cardiac glycosides disorders of cerebral circulation, impaired liver and / or kidney function, hemodialysis (risk of arterial hypotension), age up to 18 years (efficacy and safety have not been established).